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Introduction: Two small randomized controlled trials have suggested beneficial effects of antibiotic treatment in
patients with ventilator-associated tracheobronchitis (VAT). The primary aim of this study is to determine the impact
of appropriate antibiotic treatment on transition from VAT to ventilator-associated pneumonia (VAP) in critically ill
patients. The secondary objective was to determine the incidence of VAP in patients with VAT.
Methods: This was a prospective observational multicenter study. All patients with a first episode of VAT were eligible.
Patients with tracheostomy at intensive care unit (ICU) admission, and those with VAP prior to VAT were excluded. VAT
was defined using all the following criteria: fever > 38°C with no other cause, purulent tracheal secretions, positive
tracheal aspirate (≥105 cfu/mL), and absence of new infiltrate on chest X ray. Only VAP episodes diagnosed during
the 96 h following VAT, and caused by the same bacteria, were taken into account. Antibiotic treatment was at the
discretion of attending physicians. Risk factors for transition from VAT to VAP were determined using univariate
and multivariate analysis. All variables from univariate analysis with P values <0.1 were incorporated in the
multivariate logistic regression analysis.
Results: One thousand seven hundred and ten patients were screened for this study. Eighty-six, and 123 patients
were excluded for tracheostomy at ICU admission, and VAP prior to VAT; respectively. One hundred and twenty two
(7.1%) patients were included. 17 (13.9%) patients developed a subsequent VAP. The most common microorganisms
in VAT patients were Pseudomonas aeruginosa (30%), Staphylococcus aureus (18%), and Acinetobacter baumannii (10%).
Seventy-four (60%) patients received antimicrobial treatment, including 58 (47.5%) patients who received appropriate
antimicrobial treatment. Appropriate antibiotic treatment was the only factor independently associated with reduced
risk for transition from VAT to VAP (OR [95% CI] 0.12[0.02-0.59], P = 0.009). The number of patients with VAT needed to
treat to prevent one episode of VAP, or one episode of VAP related to P. aeruginosa was 5, and 34; respectively.
Conclusions: Appropriate antibiotic treatment is independently associated with reduced risk for transition from
VAT to VAP.* Correspondence: s-nseir@chru-lille.fr
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Ventilator-associated tracheobronchitis (VAT) is common
in intubated critically ill patients. This infection represents
an intermediate process between colonization of lower
respiratory tract and ventilator-associated pneumonia
(VAP). VAT is characterized by increased purulent sputum
production and lower respiratory tract inflammation
resulting in difficult weaning and prolonged duration
of mechanical ventilation [1-3].
Two recent randomized trials reported beneficial effects
of antibiotic treatment in patients with VAT. In a ran-
domized blinded placebo-controlled trial, aerosolized
antibiotics significantly reduced the incidence of subse-
quent VAP [4]. Further, aerosolized antibiotics increased
weaning from mechanical ventilation, reduced usage of
systemic antibiotics and antibiotic resistance. The impact
of systemic antibiotics on outcomes of VAT patients was
evaluated in a randomized unblinded controlled study
[5]. Antibiotic treatment increased mechanical-ventilation-
free days, and reduced the incidence of subsequent VAP
and ICU-mortality. However, these studies had some
limitations precluding definite conclusions. The beneficial
effects of antibiotic treatment in VAT patients should be
confirmed by future large multicenter studies.
Inappropriate antibiotic treatment was repeatedly iden-
tified as a major risk factor for worse outcome in patients
with severe sepsis and VAP [6]. To our knowledge, no
data are available on the impact of appropriate antibiotic
treatment on outcome in patients with VAT. Therefore,
we planned this prospective observational study to deter-
mine the impact of appropriate antibiotic treatment on
the transition from VAT to VAP. Our hypothesis is that
appropriate antibiotic treatment would be associated with
reduced risk for transition from VAT to VAP.Methods
This prospective observational study was performed in
three ICUs in Spain, Greece and France during a one-
year period. Local Institutional Review Boards (please
see Acknowledgments for more details) approved the
study, and written informed consent was obtained from
patients or their proxies to collect the data.
Patients with a first episode of VAT occurring >48 h
after intubation and mechanical ventilation were eli-
gible for this study. Patients who developed VAP before
VAT were excluded from the study, as well as patients
with tracheostomy at ICU admission, and those who
required <48 h of mechanical ventilation.
The primary objective of this study was to determine
the impact of appropriate antibiotic treatment on the
transition from VAT to subsequent VAP. The secondary
objective was to determine the incidence of VAP in patients
with VAT.Definitions
VAT is defined using all the following criteria: fever
(>38°C) with no other recognizable cause, purulent
sputum production, positive (≥105 cfu/mL) endotracheal
aspirate culture, and no radiographic signs of new pneu-
monia [7]. Only first episodes of VAT occurring more
than 48 h after starting mechanical ventilation were
taken into account. VAT was considered polymicrobial
when more than one microorganism was identified at a
significant level.
VAP was defined by the presence of new or progressive
radiographic infiltrate associated with two of the follow-
ing criteria [8]: (a) temperature >38.5°C or <36.5°C; (b)
leukocyte count >12,000/μL or <4,000/μL, and (c) puru-
lent endotracheal aspirate and positive (≥105 cfu/mL)
endotracheal aspirate, bronchoalveolar lavage (≥104 cfu/
mL), or protected specimen brush (≥103 cfu/mL).
VAP was considered as subsequent to VAT when it
was diagnosed during the 96-h period following VAT
diagnosis, and the microorganism responsible for VAP
was the same as the one responsible for VAT [9].
Multidrug-resistant (MDR) bacteria were defined as
methicillin-resistant Staphylococcus aureus, ceftazidime- or
imipenem-resistant Pseudomonas aeruginosa, Acinetobacter
baumannii, extending-spectrum β-lactamase-producing
Gram-negative bacilli, and Stenotrophomonas maltophilia.
Prior antibiotic treatment was defined as any antibiotic
treatment during the 2 weeks preceding VAT diagnosis.
Antibiotic treatment was considered appropriate when
at least one antibiotic active in vitro on all organisms
causing VAT was administrated to treat VAT. Delayed
antibiotic treatment was defined as appropriate antibiotic
treatment given to VAT patients more than 24 h after VAT
diagnosis. Severe immunosuppression was defined by the
presence of neutropenia (leucocyte count <1,000/μL or
neutrophil count <500/μL), active solid or hematological
malignancy, long-term corticosteroid therapy (≥1 mg/kg
per day for more than 1 month), or HIV infection with
CD4 < 50/μL during the previous 6 months. Chronic
obstructive pulmonary disease (COPD) was defined
according to ATS/European Respiratory Society criteria
[10]. The difference in arterial partial pressure of oxy-
gen/inspired oxygen fraction (ΔPaO2/FiO2) was defined
as the difference between the measurements on the day
of VAT diagnosis and 48 h prior to VAT diagnosis.
Data collection
All data were prospectively collected. The following data
were collected at ICU admission: age, gender, simplified
acute physiology score II (SAPS II), sequential organ failure
assessment (SOFA) score, McCabe score, admission cat-
egory (medical, surgical, trauma), comorbidities (COPD,
cirrhosis, chronic dialysis, diabetes mellitus, chronic heart
failure, immunosuppression), and cause of ICU admission.
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SOFA score, ΔPaO2/FiO2, temperature, leucocyte, C-
reactive protein (CRP), and procalcitonin (PCT) at VAT
diagnosis; microorganisms responsible for VAT, prior
antibiotic treatment, antibiotic treatment for VAT, delayed
antibiotic treatment, appropriate antibiotic treatment for
VAT, subsequent VAP, tracheostomy, total duration of
antibiotic treatment, percentage of days in the ICU with
antimicrobials, duration of invasive mechanical ventila-
tion, duration of ICU stay, and ICU mortality.
Study population
Antibiotic treatment for VAT was at the discretion of
attending physicians. Patients were placed in a semi-
recumbent position during the mechanical ventilation
period. The oropharyngeal cavity was cleaned four
times a day with chlorhexidine solution. The ventilator
circuit was not changed routinely. Tracheal cuff pressure
was monitored at least every 8 hours, and kept around
25 cm H2O. Selective digestive decontamination, and
prophylactic aerosolized antibiotics were not used during
the study period.
Infection control policy included isolation techniques,
routine screening of MDR bacteria, written antibiotic
treatment protocol, and continuous surveillance of noso-
comial infections. Routine surveillance cultures were not
performed during the study period.
Statistical analyses
SPSS software (SPSS, Chicago, IL, USA) was used for
data analysis. All P-values were two-tailed. Differences were
considered significant if P-values were <0.05. Categorical
variables are described as frequencies (%). The distribution
of continuous variables was tested for normality. Normally
distributed and skewed continuous variables are described
as mean ± SD and median (IQR); respectively.
In order to determine factors associated with transition
from VAT to VAP, patients with subsequent VAP were
compared with those without subsequent VAP using
univariate and multivariate analyses. The χ2 test or Fischer
exact test was used to compare qualitative variables, as
appropriate. Student’s t-test or the Mann-Whitney U-test
were used to compare normally distributed, and skewed
continuous variables, as appropriate. All variables from
univariate analysis with P-values <0.1 were incorporated
into the multivariate logistic regression analysis. Appropri-
ateness of antimicrobial treatment was dichotomized
for multivariate analysis, that is, appropriate antibiotic
treatment: yes or no (no antibiotic treatment or inappro-
priate antibiotic treatment). Potential interactions were
tested, and the Hosmer-Lemeshow goodness-of-fit was
calculated. The odds ratio (OR) and 95% CI was calculated
for all significant qualitative variables in univariate ana-
lysis, and all significant variables in multivariate analysis.Numbers needed to treat to prevent one VAP episode
were also calculated.
Results
Among the 1,710 patients who required invasive mech-
anical ventilation for >48 h, 86 (5.1%) patients were
excluded for tracheostomy at admission, and 123 (7.1%)
patients were excluded for VAP before VAT. Among the
1,501 remaining patients, 122 (7.1%) patients presented
VAT, including 17 (13.9%) patients with subsequent VAP
(Figure 1). Patient characteristics are presented in Table 1.
P. aeruginosa (30%), S. aureus (18%), and A. baumannii
(10%) were the most frequently isolated bacteria (Table 2).
MDR bacteria were isolated in 36% of VAT patients. VAT
episodes were polymicrobial in 13% of study patients.
Subsequent VAP
Median duration of mechanical ventilation between VAT
and subsequent VAP was 3 d (1, 3). VAP diagnosis was
performed using bronchoalveolar lavage (BAL) in eight
patients, and using quantitative tracheal aspirate in
nine patients. There was no significant difference in the
percentage of patients in whom VAP diagnosis was
performed using BAL between those having appropriate
antibiotic treatment and those having inappropriate or
no antibiotic treatment (50% (1 out of 2) versus 46.6%
(7 out of 15), P >0.999). No significant difference was
found in microoganisms, including MDR bacteria, between
patients with subsequent VAP, and those without subse-
quent VAP. No significant difference was found between
these two groups with regards to duration of mechanical
ventilation, ICU stay, or ICU mortality.
During the 96 h following VAT diagnosis, no patient
developed a VAP episode related to a microorganism
other than the one responsible for VAT. Six additional
VAP episodes were diagnosed more than 96 h after VAT
diagnosis, including two second episodes of VAP. The
percentage of VAP episodes related to MDR bacteria
was similar in VAT patients who received antimicrobials
compared with those who did not receive antimicrobials
to treat VAT (42.8% (3 out of 7) versus 43.7% (7 out of
16) P >0.999).
Antibiotic treatment
Among the 122 study patients, 74 patients (60%) received
antimicrobials for VAT, including 58 (47%) patients who
received appropriate antimicrobial treatment. No patient
received aerosolized antibiotics to treat VAT. The differ-
ence in percentage of patients with no antibiotics, with
appropriate antibiotic treatment, or with inappropriate
antibiotic treatment was significant between patients with
subsequent VAP compared with those with no subsequent
VAP. Although the difference in the rate of patients with
appropriate antibiotic treatment (2 out of 17 (11%) versus
Patients requiring MV>48h
n=1710
Eligible patients without exclusion criteria
n=1501










Figure 1 Study flowchart. MV, mechanical ventilation; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis.
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0.53)), and rate of patients with no antibiotics (13 out of
17 (76%) versus 35 out of 105 (33%), P = 0.002, 6.5 (1.9,
21)) was significant between patients with subsequent
VAP compared with those with no subsequent VAP, no
significant difference was found in the rate of patients
with inappropriate antibiotic treatment between the two
groups (2 out of 17 (11%) versus 14 out of 105 (13%),
P >0.999). Among patients who received antimicrobials
(n = 74), no significant difference was found in the rate of
VAP between those who received appropriate antibiotic
treatment compared with those who did not receive
appropriate antibiotic treatment (2 out of 58 (3.4%) versus
2 out of 16 (12.5%), P = 0.221).
Antimicrobials used in patients with inappropriate
antibiotic treatment included amoxicillin/clavulanic acid
(n = 6), ceftriaxone (n = 5), and piperacillin/tazobactam
(n = 5). The percentage of patients with antimicrobial
during the 24 h preceding VAT diagnosis was similar in
patients with subsequent VAP compared with those
with no subsequent VAP (29% (5 of 17) versus 43% (46
of 105), P = 0.301). No patient received an antibiotic
active against pathogens responsible for VAT during the
24 h preceding VAT diagnosis. Appropriate antibiotic
treatment was delayed in 10 out of 58 patients (17%). No
significant difference was found in the rate of patients
with delayed antibiotic treatment between patients with
subsequent VAP compared with those with no subsequent
VAP (1 of 17 (5.8%) versus 9 of 105 (8.5%), P >0.999).
Risk factors for subsequent VAP
Univariate analysis identified SOFA score, and leucocytes
at VAT diagnosis, and appropriate antibiotic treatment
as factors significantly associated with subsequent VAP
(Table 3). Multivariate analysis identified appropriate anti-
biotic treatment as the only factor independently associatedwith subsequent VAP (OR (95% CI) 0.12 (0.02, 0.59),
P = 0.009; P= 0.586 for Hosmer-Lemeshow goodness-of-fit).
Numbers needed to treat
The number of patients with VAT needed to treat to pre-
vent one episode of VAP was 5. The number of patients
with VAT needed to treat to prevent one episode of VAP
related to P. aeruginosa was 34.
Discussion
The main finding of the present study is that the use of
antibiotic therapy was independently associated with
reduced risk for the development of subsequent VAP:
13.9% of VAT patients developed subsequent VAP. Higher
ICU mortality, longer duration of mechanical ventilation
and ICU stay were found in patients with subsequent VAP
compared with those who did not develop subsequent
VAP. However, the difference did not reach statistical
significance.
To our knowledge this is the largest multicenter study
that prospectively follows VAT as the main ventilator-
associated complication occurring in the critically ill pa-
tient. In a prospective observational study [9] performed
on 28 VAT patients, Dallas et al. reported an incidence of
32.1% of subsequent VAP. More recently, Craven et al.
[11] reported an incidence of VAT of 11%, of which one
third later progressed to VAP. In our study this rate was
lower at 13.9%. However no information on appropriate-
ness of antibiotic treatment is provided in these studies.
The use of appropriate antibiotic therapy was the only
factor independently associated with a reduced risk of
VAP. The most likely explanation is that patients with a
bacterial load of more virulent pathogens in the respiratory
tract could benefit from antimicrobial treatment. Previous
studies demonstrated the beneficial effects of systemic
[12-14] and aerosolized [15] antibiotics in preventing
Table 1 Patient characteristics at ICU admission
Subsequent VAP P-value
Yes n = 17 No n = 105
Age, years 70 (60, 78) 64 (50, 75) 0.086
Male gender 10 (58) 68 (55) 0.786
SAPS II 54 (41, 59) 46 (35, 58) 0.307
SOFA score, mean ± SD 6.3 ± 3.2 6.4 ± 3.7 0.899
Admission category 0.999
Medical 13 (76) 80 (76)
Surgical 3 (17) 19 (18)
Trauma 1 (5) 6 (5)
Comorbidities
COPD 7 (4) 36 (34) 0.593
Cirrhosis 1 (5) 3 (2) 0.456
Chronic renal failure 1 (5) 8 (7) >0.999
Diabetes 4 (23) 17 (16) 0.491
Chronic heart failure 2 (11) 19 (18) 0.734
Immunosuppression 2 (11) 7 (6) 0.611
Cause of ICU admission
Acute exacerbation of COPD 4 (23) 16 (15) 0.478
ARDS 2 (11) 9 (8) 0.651
Shock 3 (17) 27 (25) 0.560
Community-acquired pneumonia 3 (17) 23 (21) >0.999
Healthcare-associated
pneumonia
0 (0) 9 (8) 0.358
Hospital-acquired pneumonia 0 (0) 5 (4) >0.999
Congestive heart failure 0 (0) 4 (3) >0.999
Neurologic failure 2 (11) 15 (14) >0.999
Other 6 (35) 31 (29) 0.777
Infection 10 (58) 67 (63) 0.788
Data are n (%) or median (25th, 75th IQR), unless otherwise specified. VAP,
ventilator-associated pneumonia; SAPS, simplified acute physiology score; SOFA,
sequential organ failure assessment; COPD, chronic obstructive pulmonary
disease; ARDS, acute respiratory distress syndrome.
Table 2 Microorganisms associated with ventilator
associated tracheobronchitis
Subsequent VAP
Yes n = 17 No n = 105
Microorganisms, n 20 118
Polymicrobial VAT 3 (17) 13 (7)
MDR bacteria 8 (47) 37 (35)
Gram-negative 17 (100) 91 (86)
Pseudomonas aeruginosa 4 (23)a 38 (36)a
Enterobacter species 2 (11)b 10 (9)b
Escherichia coli 1 (5) 5 (4)c
Proteus mirabilis 0 (0) 3 (2)
Citrobacter freundii 1 (5) 3 (2)
Acinetobacter baumannii 4 (23) 10 (9)
Morganella morgani 0 (0) 5 (4)
Hemophilus influenzae 1 (5) 2 (1)
Stenotrophomonas maltophilia 0 (0) 4 (3)
Klebsiella oxytoca 4 (23)d 9 (8)d
Serratia species 0 (0) 2 (1)
Gram-positive 3 (17) 27 (25)
Methicillin-resistant S. aureus 1 (5) 11 (10)
Methicillin-sensitive S. aureus 1 (5) 12 (11)
Streptococcus pneumoniae 1 (5) 4 (3)
Data are n (%). aIncluding one, and four MDR species, respectively; bincluding
one, and three MDR species, respectively; cincluding one MDR; dincluding one,
and three MDR species; respectively. P >0.1 for all comparisons between the
two groups. VAP, ventilator-associated pneumonia; VAT, ventilator-associated
tracheobronchitis; MDR, multidrug-resistant bacteria.
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antibiotic treatment is a recognized risk factor for MDR
bacteria emergence [16]. Infections caused by these
bacteria are associated with high mortality and morbidity
rates [17]. In our study, 50% of the patients developed a
subsequent VAP due to an MDR pathogen. However,
no significant difference was found in percentage of
VAP episodes related to MDR bacteria between VAP
patients who received antibiotics and those who did not
receive antibiotics. MDR pathogens have been proposed
as a risk factor for worse outcome in VAP [18], and its
risk of acquisition is based on severity of illness and
prevalence of MDR at the institution [19]. Although the
number of patients needed to treat to prevent one episode
of VAP in study patients was relatively low (n = 5), the
number of patients needed to treat to prevent one episodeof VAP related to P. aeruginosa was higher (n = 34). The
right and judicious balance of antibiotic therapy using
antibiotic stewardship optimizes antimicrobial therapy,
assures cost-effectiveness and contains bacterial resistance.
Our results suggest that inappropriate antibiotic treat-
ment is associated with worse outcomes in patients with
VAT, which is in line with previous studies performed in
VAP patients [20,21], whereas ICU mortality, duration
of mechanical ventilation and ICU stay were higher in
VAT patients with subsequent VAP compared with those
without subsequent VAP. It is important to highlight,
that the differences did not reach statistical significance
probably because of a limited sample size. In addition,
due to our definition of subsequent VAP, some patients
classified as having no subsequent VAP had pneumonia
diagnosed after 96 h of VAT diagnosis, or pneumonia
diagnosed during the 96 h following VAT diagnosis, but
caused by a different microorganism than the one causing
VAT. The development of VAP has been associated with
worse outcomes [22-24] and the results from this study
show that subsequent VAP might be decreased with
the use of appropriate antibiotic treatment. Other authors
[25] have proposed the use of pre-emptive broad-spectrum
Table 3 Patient characteristics during ICU stay
Subsequent VAP P-value
Yes n = 17 No n = 105
At VAT diagnosis
Duration of prior mechanical ventilation, d 8 (3, 18) 11 (6, 17) 0.689
Prior antibiotic treatment 11 (64) 68 (64) >0.999
SOFA score 6 (6, 9) 4 (3, 7) 0.029
ΔPaO2/FiO2 10 (−30, 50) −12 (−66, 39) 0.221
Temperature 38 (37.5, 38.6) 38 (37.6, 38.4) 0.829
Leucocytes 13.4 (10, 18.9) 10.6 (7.2, 14.6) 0.034
PCT 1.1 (0.7, 1.85) 0.55 (0.22, 3) 0.515
CRP 52 (18, 135) 60 (14, 126) 0.825
Antibiotic treatment 0.002
No 13 (76) 35 (33)
Yes 4 (23) 70 (66)
Appropriate 2 (11) 56 (53)
Inappropriate 2 (11) 14 (13)
During ICU stay
Tracheostomy 5 (29) 33 (31) >0.999
Duration of antibiotic treatment, d 18 (15, 22) 18 (11, 30) 0.819
Percentage of days in the ICU with antimicrobials 48 (0, 70) 51 (0, 70) 0.595
Duration of mechanical ventilation, d 27 (16, 29) 22 (13, 35) 0.553
Length of ICU stay, d, mean ± SD 43 ± 50 32 ± 21 0.137
ICU mortality 9 (52) 37 (35) 0.185
Data are n (%) or median (25th, 75th IQR), unless otherwise specified. SOFA, sequential organ failure assessment; PCT, procalcitonin; CRP, C-reactive protein; VAT,
ventilator-associated pneumonia; ΔPaO2/FiO2: difference in arterial partial pressure of oxygen/inspired oxygen fraction.
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Whereas this strategy, only slightly reduced the inci-
dence and onset of both VAP and VAT, there was an
increased rate of MDR pathogens (linezolid-resistant
Staphylococcus spp.).
Leukocyte count at VAT diagnosis was significantly
higher in patients with subsequent VAP compared with
those with no subsequent VAP. However, leukocyte count
was not independently associated with subsequent VAP.
In addition, no significant difference was found in CRP
and PCT levels between the two groups. Further, the
percentage of patients with VAP diagnosed using BAL
was similar in patients with appropriate or inappropriate
antibiotic treatment, suggesting that VAP episodes were
not misdiagnosed because of the low specificity of tracheal
aspirate. Although computed tomography (CT) was not
performed in all VAT patients to rule out the presence of
an infiltrate, chest radiographs were all interpreted by two
independent physicians to diagnose a new infiltrate. When
agreement was not achieved, an independent radiologist
was consulted. Another argument against the presence of
early VAP at VAT diagnosis is the absence of significant
modification in the PaO2/FiO2 ratio. However, alteration
of oxygenation is not constant in VAP patients.Recent studies suggest that by using ventilator bundles,
an important decrease in the VAP rate could be obtained.
Muszynski et al. [26] found that in a pediatric population
a successful implementation of an evidence-based-care
bundle to prevent ventilator-associated infection was
associated with decreased incidence of VAT. However
the present study shows that not all episodes of lower
respiratory tract infection can be prevented, but can
only be modified by breaking the bridge of transition
from VAT to VAP based on correct therapy.
Our study has some limitations. First, we diagnosed
VAT based on chest radiographs and CT was not done.
Further, the presence of a pulmonary infiltrate on CT
performed for other reasons was not evaluated. The use
of CT has been proposed by some authors for VAT versus
VAP differentiation in patients with doubtful infiltrates
such as ARDS, pneumonia and/or congestive heart failure
[27]. However, a baseline examination is needed to diag-
nose a new infiltrate. Performing a CT scan of the chest in
all ICU admissions is not feasible because of the side
effects related to the transport of patients outside the
ICU, and the cost-effectiveness of such a strategy [28].
Therefore, VAT could have been confounded with early
VAP because of the difficult interpretation of the chest
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definition for subsequent episodes of VAP after VAT.
However we have used strict criteria for such differenti-
ation based on the development of a new or progressive
infiltrate and the isolation in significant growth 96 h after
initial diagnosis of VAT. Although this definition was used
in a previous study [9], VAP episodes diagnosed >96 h
after VAT could still be related to inappropriate antibiotic
treatment. However, we repeated our analysis using a
7-day period between VAT and VAP diagnosis, and
similar results were found (data not shown). Third,
although practices in the management of VAT and
VAP were identical in the three participating ICUs,
the study protocol did not include routine surveillance
of tracheal aspirate cultures but only collection of
respiratory samples when VAT or VAP were suspected on
clinical and biological grounds. Although this reflects daily
clinical practice, routine surveillance cultures could have
been useful in increasing the rate of appropriate antibiotic
treatment, and decreasing the rate of delayed antibiotic
treatment. Previous studies performed in patients with
VAP suggested beneficial effects of routine surveillance
cultures, especially in patients with MDR [18,29]. How-
ever, a recent study found the ATS/IDSA guidelines-
based approach to be more accurate than the tracheal
aspirate-based strategy for prescribing appropriate initial
empirical antibiotics in VAP, unless a sample was available
within ≤2 days of the onset of VAP [30]. Fourth, the most
important limitation is probably the observational design
of the study, and the absence of randomization for
antibiotic treatment. Finally, no significant difference
was found in the subsequent VAP rate between patients
with inappropriate antibiotic treatment and other study
groups. This is probably related to small number of patients
with inappropriate antibiotic treatment (n = 16). The study
was also underpowered to detect the impact of appropriate
antibiotic treatment for VAT on subsequent VAP related
to MDR.
Conclusion
In conclusion, appropriate antibiotic treatment is inde-
pendently associated with decreased risk of subsequent
VAP in patients with VAT. Further large multicenter
studies are required to confirm our results.
Key messages
 Appropriate antibiotic treatment is independently
associated with decreased risk of subsequent VAP in
patients with VAT.
 Among VAT patients, 13.9% developed subsequent
VAP.
 Higher mortality rates, longer duration of
mechanical ventilation and ICU stay were found inVAT patients with subsequent VAP compared with
those with no subsequent VAP. However, the
difference was not statistically different.
 The number of patients with VAT needed to treat to
prevent one episode of VAP, or one episode of VAP
related to P. aeruginosa was 5, and 34, respectively.
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